---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-263831"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2026-06-09T20:28:58+00:00"
generated_at: "2026-06-09T20:30:23.737696+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# SL-325 Phase 1 shows 3.7% ADA, durable DR3 blockade; 96% of warrants exercised for ~$49.3M additional proceeds.

## Summary
- Phase 1: ADA detected in only 3.7% (2/54) of SL-325 recipients; low titer (≤16) with no PK/RO impact.
- Complete DR3 occupancy at all doses ≥0.1 mg/kg; PK modeling suggests >3 months blockade at doses ≥1 mg/kg.
- No serious TEAEs; all TRAEs Grade 1; no DR3 agonism or lymphocyte proliferation observed.
- RECEPTIVE-CD1 Phase 2b in Crohn's expected to start Q3 2026; primary endpoint endoscopic response at Week 12.
- Warrant exercise for ~50.6M shares (96% of Aug 2025 placement) yields ~$54.9M gross; cash runway into 2029.

## SEC filing metadata
- accession: 0001193125-26-263831
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2026-06-09T20:28:58+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000119312526263831/0001193125-26-263831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000119312526263831/d120796d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-263831
- JSON: https://secwatch.observer/filing/0001193125-26-263831.json
- Plain text: https://secwatch.observer/filing/0001193125-26-263831.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.